After Today’s Huge Increase, Is InflaRx N.V. (IFRX)’s Near-Term Analysis Positive?

April 17, 2018 - By Vivian Currie

The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock increased 5.35% or $1.86 during the last trading session, reaching $36.62. About 115,886 shares traded or 89.96% up from the average. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.
The move comes after 7 months positive chart setup for the $857.31M company. It was reported on Apr, 17 by Barchart.com. We have $39.92 PT which if reached, will make NASDAQ:IFRX worth $77.16M more.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $857.31 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

InflaRx N.V. (NASDAQ:IFRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.